课题基金 / 基金详情

Analysis of newly identified anglogenic genes and the signal inhibition for tumor dormancy therapy

Analysis of newly identified anglogenic genes and the signal inhibition for tumor dormancy therapy
新发现的血管生成基因分析及肿瘤休眠治疗的信号抑制
批准号:
14571141
负责人:
TANAKA Shinji
金额:
$2.56万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2002
资助国家:
日本
项目状态:
已结题
起止时间:
2002 至 2003

项目摘要

项目成果

TANAKA Shinji的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
In vivo progression to malignancy is characterized by the switch to an angiogenic phenotype. The angiogenic switch is a critical control point for tumor expansion. The ability of a tumor to become neovascularized permits rapid expansion of tumor growth and increases the likelihood of metastases. The genetic alterations which accompany the switch to the angiogenic phenotype are unknown. Discoveries of such genes lead to comprehension of molecular mechanisms of the tumor progression, as well as development of novel therapeutic tools. We have isolated a novel "angiogenic switch molecule", Angiopoietin-2, upregulated specifically in hypervascular hepatocellular carcinoma (HCC). Angiopoietin family proteins have been originally identified to be ligands of vascular endothelial receptor of tyrosine kinase Tie2. Ectopic expression of Angiopoietin-2 promotes the rapid development of human HCCs and produces hemorrhage within tumors in nude mice. These results suggest a role for Angiopoietin-2 in the neovascularization of HCC. In vitro expression of a dominant-negative construct, containing a soluble Tie2 ectodomain (sTie2), led to Angiopoietin protein interaction, inhibition of endogenous Tie2 phosphorylation in vascular endothelial cells. Tumorigenicity with angiogenesis was suppressed by in vivo gene transfer and sTie2 expression in a murine HCC model, suggesting a possible role for Angiopoietin/Tie2 signaling in the induction of HCC neovascularization, and disease progression. More important, inhibition of the Angiopoietin/Tie2 signal transduction cascade is a promising approach for HCC treatment. Furthermore, we have identified two novel genes of the CCN family involved in angiogenesis ; WISP1v (Genbank AB034122) and WISP3v (Genbank AB075040). Gene transfection analysis revealed that WISP1v and WISP3v function as regulators of cell migration. Further analysis should be required to clarify the roles of WISPs in angiogenesis.
期刊论文(72)
专著(0)
科研奖励(0)
会议论文
Tanaka S, et al.: "Role of Expression of Focal Adhesion Kinase on Progression in Hepatocellular Carcinoma."Clin Cancer Res. in press.
Tanaka S 等人:“粘着斑激酶的表达对肝细胞癌进展的作用”。《临床癌症研究》。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Tanaka S, Sugimachi K, Kameyama T, Maehara Si, Shirabe K, Shimada M, Wands JR, Maehara Y.: "Human WISP1v, a member of CCN family, is associated with invasive cholangiocarcinoma."Hepatology. 37(5). 1122-1129 (2003)
Tanaka S、Sugimachi K、Kameyama T、Maehara Si、Shirabe K、Shimada M、Wands JR、Maehara Y.:“人类 WISP1v 是 CCN 家族的成员,与侵袭性胆管癌相关。”肝病学。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Tanaka S, et al.: "Tie2 vascular endothelial receptor expression and function in hepatocellular carcinoma"Hepatology. 35(4). 861-867 (2002)
Tanaka S 等人:“肝细胞癌中 Tie2 血管内皮受体的表达和功能”肝病学。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Yamashita Yi, Shimada M, Tannka S, Okamoto M, Miyazaki Ji, Sugimachi K.: "Electroporation-mediated tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L gene therapy for hepatocelhilar carcinoma."Human Gene Therapy. 13(2). 275-286 (2002)
Yamashita Yi、Shimada M、Tannka S、Okamoto M、Miyazaki Ji、Sugimachi K.:“电穿孔介导的肿瘤坏死因子相关凋亡诱导配体 (TRAIL)/Apo2L 基因治疗肝细胞癌。”人类基因治疗。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
36
    学校安全の推進の為の組織的対応力の向上を目指した校内研修プログラムの開発
    • 批准号:
      21H03974
    • 项目类别:
      Grant-in-Aid for Encouragement of Scientists
    • 资助金额:
      $0.28万
    • 财政年份:
      2021
    • 负责人:
      TANAKA Shinji
    • 依托单位:
    安全に関する資質・能力を身に着けることを目指した、安全教育カリキュラムの構築
    • 批准号:
      19H00081
    • 项目类别:
      Grant-in-Aid for Encouragement of Scientists
    • 资助金额:
      $0.33万
    • 财政年份:
      2019
    • 负责人:
      TANAKA Shinji
    • 依托单位:
    Virtue Ethics in Plato's Politeia
    • 批准号:
      18K00011
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $1.25万
    • 财政年份:
      2018
    • 负责人:
      TANAKA Shinji
    • 依托单位:
    Develoment of advanced therapy targeting tumor heterogeneity in refractory cancers
    • 批准号:
      16H02670
    • 项目类别:
      Grant-in-Aid for Scientific Research (A)
    • 资助金额:
      $30.28万
    • 财政年份:
      2016
    • 负责人:
      TANAKA Shinji
    • 依托单位:
    国内基金
    海外基金
    METTL3以m6A-HuR依赖性调控ETS1/Tie2促进乳牙干细胞诱导血管生成的机制研究
    • 批准号:
      2025JJ80529
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2025
    • 负责人:
      覃建
    • 依托单位:
    Tie2通过靶向NLRP3泛素化调控巨噬细胞焦亡和NLRP3炎症小体激活改善急性肺损伤的机制研究
    • 批准号:
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2025
    • 负责人:
      徐佳妮
    • 依托单位:
    血管内皮细胞TIE2突变通过调控TNFSF10-BK/Ca离子通道影响静脉畸形平滑肌细胞表型转化过程的机制研究
    积雪草苷靶向Sirt3/Ang1/Tie2信号轴介导周细胞—内皮细胞间通讯阻抑腹膜微血管损伤
    • 批准号:
      82305226
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      30.00万元
    • 批准年份:
      2023
    • 负责人:
      唐蕾
    • 依托单位: